Log In
Print this Print this

BAL3833, CCT3833

  Manage Alerts
Collapse Summary General Information
Company The Institute of Cancer Research
DescriptionInhibitor of multiple RAF proteins, including BRAF
Molecular Target BRAF
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation
PartnerBasilea Pharmaceutica Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today